ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.
Saved in:
| Title: | ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report. |
|---|---|
| Authors: | Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Grauslund M; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Berger SMS; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Costa JC; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Koffeldt PR; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Sørensen JB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. |
| Source: | Translational lung cancer research [Transl Lung Cancer Res] 2024 Sep 30; Vol. 13 (9), pp. 2453-2462. Date of Electronic Publication: 2024 Sep 26. |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Pioneer Bioscience Publishing Company Country of Publication: China NLM ID: 101646875 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2218-6751 (Print) Linking ISSN: 22186751 NLM ISO Abbreviation: Transl Lung Cancer Res Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2218-6751 |
|---|---|
| DOI: | 10.21037/tlcr-24-439 |
